We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quanterix Acquires Magnetic Bead Tech Firm Emission

By LabMedica International staff writers
Posted on 18 Dec 2024

Quanterix Corporation (Billerica, MA, USA), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, has acquired EMISSION iNC (Georgetown, TX, USA), expanding its technology capabilities through vertical integration of proprietary bead technology.

Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs made possible through its unparalleled sensitivity and flexibility. The company’s Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum, or plasma, with the ability to quantify proteins far lower than the Limit of Quantification (LoQ) of conventional analog methods. EMISSION manufactures large-scale, highly uniform dye-encapsulating magnetic beads designed for low and mid-plex assays and a mid-plex platform that reads its proprietary beads. Vertically integrating EMISSION will allow Quanterix to secure the use of EMISSION’s highly controlled beads in Quanterix’s next-generation platform and to develop a new multi-plex segment targeting third parties.


Image: The CUBE mid-plex platform is up to 100X more sensitive than legacy systems (Photo courtesy of EMISSION)
Image: The CUBE mid-plex platform is up to 100X more sensitive than legacy systems (Photo courtesy of EMISSION)

“As we expand our technology stack toward higher multi-plex and multi-omic capabilities, it is imperative we control core components,” said Masoud Toloue, Chief Executive Officer of Quanterix. “EMISSION’s proprietary bead technology has already been validated on our upcoming new Simoa platform and will enable us to provide OEM beads to other non-Quanterix platforms. We look forward to welcoming EMISSION’s innovations and colleagues to the Quanterix team.”

“EMISSION was built on our high-quality bead technology and we believe that better beads and ultimately better multi-plex assays should be within everyone’s reach,” added Van Chandler, CEO of EMISSION. “Having known and worked with the Quanterix team for years, we are excited to join forces, as we support the upcoming Simoa platform and a shared vision for expanding the technology’s reach to all labs.”

Related Links:
Quanterix Corporation
EMISSION iNC


Gold Member
Turnkey Packaging Solution
HLX
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Autoimmune Disease Test
Anti-Centromere B ELISA Test
New
Coccidioidomycosis Test
Premier Coccidioides Antibody Test

Latest Industry News

Worldwide Initiative Aims to Develop Globally Generalizable Blood-Based Tests for Alzheimer’s Disease

Hologic Enters into Agreement with CDC for H5N1 Bird Flu Test Development

LGC Acquires German Quality Controls Maker DiaMex